ClinConnect ClinConnect Logo
Search / Trial NCT03504228

Prospective Single Arm CAS - ROADSAVER Study

Launched by TERUMO EUROPE N.V. · Apr 19, 2018

Trial Information

Current as of May 29, 2025

Completed

Keywords

ClinConnect Summary

1. Baseline Assessments

The patient will be assessed in accordance with the hospital standard of care for patients treated with carotid artery stenting procedure, which in general includes:
* Informed consent for data collection
* Demographics
* Medical History
* Medication record
* Physical examination
* Carotid Duplex Ultrasound
* Neurological Assessment
* Diffusion weighted Magnetic Resonance Imaging (DW-MRI)
* Procedural angiography

Baseline assessments will be performed prior to the index procedure and documented in the patient medical record. Baselin...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The patient has a non-occlusive and non-thrombotic carotid artery stenosis and is eligible to be treated with Roadsaver Carotid Stent as per the Instructions for Use (IFU)
  • The patient is at least 18 years of age
  • The patient has a life expectancy of at least 12 months from the date of the index procedure
  • The patient is able and willing to provide a signed IRB-/EC-approved informed consent form prior to participation
  • Exclusion Criteria:
  • - Any condition that makes patient unsuitable for percutaneous transluminal angioplasty (PTA), including intolerance or allergy to any material used and accompanying therapy

About Terumo Europe N.V.

Terumo Europe N.V. is a leading global medical technology company dedicated to advancing healthcare through innovative solutions. With a strong focus on the development and manufacturing of a wide range of medical devices, including vascular intervention, surgical, and blood management products, Terumo Europe N.V. is committed to enhancing patient outcomes and improving the efficiency of healthcare delivery. The organization adheres to rigorous clinical trial standards and regulatory compliance, ensuring that its products meet the highest quality and safety benchmarks. By fostering collaboration with healthcare professionals and leveraging cutting-edge research, Terumo Europe N.V. aims to contribute significantly to the evolution of medical practices and patient care across Europe and beyond.

Locations

Madrid, , Spain

Leuven, , Belgium

Barcelona, , Spain

Belgrade, , Serbia

Tenerife, , Spain

Passau, , Germany

Bonheiden, , Belgium

Novi Sad, , Serbia

Pécs, , Hungary

Kortrijk, , Belgium

Toledo, , Spain

Dendermonde, , Belgium

Suhl, , Germany

Groningen, , Netherlands

Aalst, , Belgium

Budapest, , Hungary

Szeged, , Hungary

A Coruña, , Spain

Jaén, , Spain

Barcelona, , Spain

San Sebastián, , Spain

Grenoble, , France

Riga, , Latvia

Skopje, , North Macedonia

Skopje, , North Macedonia

Oldenburg, , Germany

Palma De Mallorca, , Spain

Münster, , Germany

Ostrava, , Czechia

Bratislava, , Slovakia

Mannheim, , Germany

Prague, , Czechia

Bayonne, , France

Marseille, , France

Nancy, , France

Berlin, , Germany

Berlin, , Germany

Bruchsal, , Germany

Flensburg, , Germany

Frankfurt/Main, , Germany

Karlsbad, , Germany

Radebeul, , Germany

Ulm, , Germany

Budapest, , Hungary

Kaposvár, , Hungary

Kecskemét, , Hungary

Székesfehérvár, , Hungary

Nieuwegein, , Netherlands

Bydgoszcz, , Poland

Kraków, , Poland

Kraków, , Poland

Vila Nova De Gaia, , Portugal

Belgrad, , Serbia

Nitra, , Slovakia

Girona, , Spain

Marbella, , Spain

Valladolid, , Spain

Patients applied

0 patients applied

Trial Officials

Ihsen Merioua, MD

Study Director

Ihsen.Merioua@terumo-europe.com

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials